Relationship between serum Pre-B cell colony-enhancing factor/visfatin and atherosclerotic parameters in chronic hemodialysis patients

American Journal of Nephrology

Volumn 29, Issue 1, 2008, Pages 31-35

  Kato, Akihiko ^a   Odamaki, Mari ^a   Ishida, Junko ^a   Hishida, Akira ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Asymmetric dimethylarginine; Hemodialysis; High sensitive C reactive protein; Pulse wave velocity; Visfatin

Indexed keywords

ADIPONECTIN; BICARBONATE; C REACTIVE PROTEIN; SERUM ALBUMIN; VISFATIN;

ABDOMINAL AORTA; ABDOMINAL SUBCUTANEOUS FAT; ADULT; AGED; ALBUMIN BLOOD LEVEL; ANKLE BRACHIAL INDEX; AORTA WALL; ARTERY CALCIFICATION; ARTICLE; ATHEROSCLEROSIS; BODY MASS; DIALYSATE; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INTRAABDOMINAL FAT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PULSE WAVE; TREATMENT DURATION;

AGED; AORTA; ARGININE; ARTERIES; ATHEROSCLEROSIS; B-LYMPHOCYTES; BODY MASS INDEX; C-REACTIVE PROTEIN; CHRONIC DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RENAL DIALYSIS;

EID: 47949101183     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000148648     Document Type: Article

References (23)

1. Samel B, Sun Y, Stearns G, et al: Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994;14:1431-1437.
2. van der Veer E, Nong Z, O'Neil C, et al: Pre-B-cell colony-enhancing factor regulates NAD+-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. Circ Res 2005;97:25-34.
3. Luck T, Malam Z, Marshall JC: Pre-B-cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J Leuk Biol 2008;83:804-816.
4. Fukuhara A, Matsuda M, Nishizawa M, et al: Retraction. Science 2007;317:565.
5. Kim SR, Bae YH, Bae SK, et al: Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-κB activation in endothelial cells. Biochim Biophys Acta 2008;1783:886-895.
6. Adya R, Tan BK, Chen J, Randeva HS: Nuclear factor κB induction by visfatin in human vascular endothelial cells: role in MMP-2/9 production and activation. Diabetes Care 2008;31:758-760.
7. Dahl TB, Yndestad A, Skjelland M, et al: Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis. Possible role in inflammation and plaque destabilization. Circulation 2007;115:972-980.
8. Takebayashi K, Suetsugu M, Wakabayashi S, et al: Association between plasma visfatin and vascular endothelial function on patients with type 2 diabetes mellitus. Metabolism 2007;56:451-458.
9. Kostapanos MS, Derdemezis CS, Filippatos TD, et al: Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia. Eur J Pharmacol 2008;578:249-252.
10. Kato A, Odamaki M, Ishida J, Hishida A: Association of high-molecular-weight to total adiponectin ratio with pulse wave velocity in hemodialysis patients. Nephron Clin Pract 2008;109:c18-c24.
11. Jia SH, Parodo J, Kapus A, et al: Pre-B-cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004;114:1318-1327.
12. Ye SQ, Simon BA, Maloney JP, et al: Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury. Am J Respir Crit Care Med 2005;171:361-370.
13. Brentano F, Schorr O, Ospelt C, et al: Pre-B-cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum 2007;56:2829-2839.
14. Seo JA, Jang ES, Kim BG, et al: Plasma visfatin levels are positively associated with circulating interleukin-6 in apparently healthy Korean women. Diabetes Res Clin Pract 2008;79:108-111.
15. Axelsson J, Witasp A, Carrero JJ, et al: Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am J Kidney Dis 2007;49:237-244.
16. Chen CC, Li TC, Li CI, et al: The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women. Metabolism 2007;56:1216-1220.
17. Ingelsson E, Larson MG, Fox CS, et al: Clinical correlates of circulating visfatin levels in a community-based sample. Diabetes Care 2007;30:1278-1280.
18. Yilmaz MI, Saglam M, Carrero JJ, et al: Serum visfatin concentration and endothelial dysfunction on chronic kidney disease. Nephrol Dial Transplant 2008;23:959-965.
19. Yilmaz MI, Saglam M, Qureshi AR, et al: Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transplant 2008;23:1621-1627.
20. Yilmaz MI, Saglam M, Caglar K, et al: The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 2006;47:42-50.
21. Malavazos AE, Ermetici F, Cereda E, et al: Epicardial fat thickness: relationship with plasma visfatin and plasminogen activator inhibitor-1 levels in visceral obesity. Nutr Metab Cardiovasc Dis, in press.
22. de Luis DA, Sagrado MG, Conde R, et al: Effect of a hypocaloric diet on serum visfatin in obese non-diabetic patients. Nutrition, in press.
23. Frydelund-Larsen L, Akerstrom T, Nielsen S, et al: Visfatin mRNA expression in human subcutaneous adipose tissue is regulated by exercise. Am J Physiol Endocrinol Metab 2007;292:E24-E31.